Tesamorelin

FDA-approved dose (Egrifta/Egrifta SV): 2 mg subcutaneously once daily, injected into the abdomen with site rotation. Approved for HIV-associated lipodystrophy. Treatment effect should be assessed after initial treatment period; discontinue if no improvement in visceral fat. Off-label research contexts may discuss similar daily dosing.

Binds to the GHRH receptor on pituitary somatotrophs, stimulating endogenous growth hormone synthesis and pulsatile secretion through the cAMP/PKA pathway.

Enhances both basal and pulsatile GH secretion patterns while maintaining physiological feedback regulation via somatostatin.

Increases circulating IGF-1 levels through stimulation of hepatic IGF-1 production secondary to elevated GH, supporting tissue anabolism.

GH-mediated activation of lipolysis preferentially targets visceral adipose tissue, reducing trunk fat accumulation.

FDA-approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. Demonstrated significant reduction in trunk fat in two Phase 3 RCTs.

Increases lean body mass while reducing visceral fat, improving waist-to-hip ratio and metabolic markers.

Restores IGF-1 levels toward youthful ranges, supporting tissue repair, muscle maintenance, and metabolic function.

Emerging research suggests potential neuroprotective effects and cognitive benefits through GH/IGF-1 axis modulation.

May improve triglyceride levels and other lipid markers through GH-mediated metabolic effects.

Therapeutic peptides are short-chain amino acids that regulate cellular functions and facilitate bio...

The American journal of sports medicine · Cory K Mayfield, Ioanna K Bolia, Cailan L Feingold, Eric H L...

Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, g...

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · Omar F Rahman, Steven J Lee, William A Seeds

Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among people wi...

Current opinion in HIV and AIDS · Arijeet K Gattu, Lindsay T Fourman

In people with HIV who are virally suppressed with antiretroviral therapy, abdominal obesity (AO) is...

The Journal of infectious diseases · Ronald J Ellis, Florin Vaida, Keren Hu, Michael Dube, Brook ...

Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV ...

AIDS (London, England) · Samuel C Russo, Mollie W Ockene, Allison K Arpante, Julia E ...